News
Pamalican Asset Management just snagged 6,900 shares of Regeneron Pharmaceuticals, making the biotech giant its 16th largest ...
Research analysts at Leerink Partnrs dropped their FY2026 earnings per share estimates for Alnylam Pharmaceuticals in a ...
Equities research analysts at Leerink Partnrs reduced their Q1 2025 EPS estimates for shares of Regeneron Pharmaceuticals in a research report issued on Tuesday, April 1st. Leerink Partnrs analyst D.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback